Cordero, P., Gomez-Uriz, A
(2) Hillary H Le, Suleyman S Cinaroglu, Elise C Manalo, Aysegul Ors, et al (2021) Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine, 2021 Oct 21, Volume 73, Page 103646
Ideal candidates Patients who benefit most from Strive compounded tirzepatide typically share several characteristics

Decreased stomach acid Atrophic gastritis Autoimmune pernicious anaemia Helicobacter pylori Gastrectomy, partial or complete Gastric bypass surgery (weight loss) Intestinal resection Partial or complete ileectomy Gastrointestinal neoplasms Malnutrition Eating disorders anorexia bulimia Inadequate diet Vegetarianism / veganism Malabsorption syndromes Alcoholism Crohns disease Coeliac disease (gluten enteropathy) Dipphyllobothrium infection blind loop syndrome diverticulosis inflammatory bowel disease small bowel overgrowth tropical sprue gastric irradiation ileal irradiation (bladder,cervix, uterus,prostate) Inborn errors of B12 metabolism Transcobalamin II deficiency Pancreatic exocrine insufficiency & Chronic pancreatitis Imerslund Gresbeck syndrome Zollinger Ellison Syndrome Bacterial overgrowth (small bowel) Fish tapeworm Advanced liver disease Drug induced causes Please note

Each BPC-157 10mg order is carefully packed to protect against temperature fluctuations, moisture exposure, and physical damage during transit
BPC-157 is NOT suitable for individuals with: Active cancer (as it promotes new blood vessel growth)